Asset Details

MbrlCatalogueTitleDetail

Do you wish to reserve the book?

Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer

by McJannett, Margaret , Reaume, M. Neil , Zielinski, Robert R , Begbie, Stephen , Chi, Kim N , Parulekar, Wendy , Yip, Sonia , Parnis, Francis , Frydenberg, Mark , Chowdhury, Simon , McCaffrey, John , Horvath, Lisa G , Marx, Gavin , Sandhu, Shahneen K , McDermott, Ray , North, Scott A , Stockler, Martin R , Joshua, Anthony M , Thomson, Alastair , Sweeney, Christopher J , Coskinas, Xanthi , Zhang, Alison Y , Pook, David W , Tan, Alvin , Davis, Ian D , Williams, Scott G , Martin, Andrew J , Tu, Emily , Hague, Wendy E , Lawrence, Nicola J , Tan, T. Hsiang , Vera-Badillo, Francisco

in Adenocarcinoma - drug therapy / Adenocarcinoma - mortality / Adenocarcinoma - secondary / Aged / Androgen Receptor Antagonists - adverse effects / Androgen Receptor Antagonists - therapeutic use / Androgen receptors / Androgens / Antineoplastic Combined Chemotherapy Protocols - adverse effects / Antineoplastic Combined Chemotherapy Protocols - therapeutic use / Bone Neoplasms - drug therapy / Bone Neoplasms - secondary / Cancer therapies / Castration / Clinical trials / Design / Digestive System Neoplasms - drug therapy / Digestive System Neoplasms - secondary / Fatigue - chemically induced / Follow-Up Studies / Humans / Kaplan-Meier Estimate / Male / Medical imaging / Medical research / Metastases / Metastasis / Middle Aged / Patients / Phenylthiohydantoin - adverse effects / Phenylthiohydantoin - analogs & derivatives / Phenylthiohydantoin - therapeutic use / Progression-Free Survival / Prostate cancer / Prostate-specific antigen / Prostatic Neoplasms - drug therapy / Prostatic Neoplasms - mortality / Prostatic Neoplasms - pathology / Seizures / Seizures - chemically induced / Survival / Testosterone

2019

Yes Please

Hey, we have placed the reservation for you!

By the way, why not check out events that you can attend while you pick your title.

Oops! Something went wrong.

Looks like we were not able to place the reservation. Kindly try again later.

Are you sure you want to remove the book from the shelf?

Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer

2019

Confirm

Do you wish to request the book?

Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer

2019

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy

How would you like to get it?

Submit

We have requested the book for you!

Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.

Oops! Something went wrong.

Looks like we were not able to place your request. Kindly try again later.

Journal Article

Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer

McJannett, Margaret,

Reaume, M. Neil,

Zielinski, Robert R,

Begbie, Stephen,

Chi, Kim N,

Parulekar, Wendy,

Yip, Sonia,

Parnis, Francis,

Frydenberg, Mark,

Chowdhury, Simon,

McCaffrey, John,

Horvath, Lisa G,

Marx, Gavin,

Sandhu, Shahneen K,

McDermott, Ray,

North, Scott A,

Stockler, Martin R,

Joshua, Anthony M,

Thomson, Alastair,

Sweeney, Christopher J,

Coskinas, Xanthi,

Zhang, Alison Y,

Pook, David W,

Tan, Alvin,

Davis, Ian D,

Williams, Scott G,

Martin, Andrew J,

Tu, Emily,

Hague, Wendy E,

Lawrence, Nicola J,

Tan, T. Hsiang,

Vera-Badillo, Francisco

2019

Overview

In men with metastatic, hormone-sensitive prostate cancer who were receiving testosterone suppression, the addition of enzalutamide led to significantly longer progression-free and overall survival than the addition of standard nonsteroidal antiandrogen therapy. The better outcome was less clear among patients who had received docetaxel.

Share this book

Add to My Shelf

Publisher

Massachusetts Medical Society

Subject

Adenocarcinoma - drug therapy

/ Adenocarcinoma - mortality

/ Adenocarcinoma - secondary

/ Aged

/ Androgen Receptor Antagonists - adverse effects

/ Androgen Receptor Antagonists - therapeutic use

/ Androgen receptors